273 related articles for article (PubMed ID: 36455638)
1. Chronic pain in Alzheimer's disease: Endocannabinoid system.
Blanton H; Reddy PH; Benamar K
Exp Neurol; 2023 Feb; 360():114287. PubMed ID: 36455638
[TBL] [Abstract][Full Text] [Related]
2. Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia.
Wei YJ; Schmidt S; Chen C; Fillingim RB; Reid MC; DeKosky S; Solberg L; Pahor M; Brumback B; Winterstein AG
Alzheimers Res Ther; 2021 Apr; 13(1):78. PubMed ID: 33883028
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease.
Rapaka D; Bitra VR; Challa SR; Adiukwu PC
Neuropeptides; 2021 Dec; 90():102196. PubMed ID: 34508923
[TBL] [Abstract][Full Text] [Related]
4. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.
Bedse G; Romano A; Lavecchia AM; Cassano T; Gaetani S
J Alzheimers Dis; 2015; 43(4):1115-36. PubMed ID: 25147120
[TBL] [Abstract][Full Text] [Related]
5. Roles of Cannabidiol in the Treatment and Prevention of Alzheimer's Disease by Multi-target Actions.
Zhang XB; Li J; Gu J; Zeng YQ
Mini Rev Med Chem; 2022; 22(1):43-51. PubMed ID: 33797364
[TBL] [Abstract][Full Text] [Related]
6. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
7. Non-Cancer Chronic Pain Conditions and Risk for Incident Alzheimer's Disease and Related Dementias in Community-Dwelling Older Adults: A Population-Based Retrospective Cohort Study of United States Medicare Beneficiaries, 2001-2013.
Khalid S; Sambamoorthi U; Innes KE
Int J Environ Res Public Health; 2020 Jul; 17(15):. PubMed ID: 32751107
[TBL] [Abstract][Full Text] [Related]
8. Can Musical or Painting Interventions Improve Chronic Pain, Mood, Quality of Life, and Cognition in Patients with Mild Alzheimer's Disease? Evidence from a Randomized Controlled Trial.
Pongan E; Tillmann B; Leveque Y; Trombert B; Getenet JC; Auguste N; Dauphinot V; El Haouari H; Navez M; Dorey JM; Krolak-Salmon P; Laurent B; Rouch I;
J Alzheimers Dis; 2017; 60(2):663-677. PubMed ID: 28922159
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of the endocannabinoid system for Alzheimer's disease.
Karl T; Cheng D; Garner B; Arnold JC
Expert Opin Ther Targets; 2012 Apr; 16(4):407-20. PubMed ID: 22448595
[TBL] [Abstract][Full Text] [Related]
10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
11. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study.
Hamina A; Taipale H; Tanskanen A; Tolppanen AM; Karttunen N; Pylkkänen L; Tiihonen J; Hartikainen S
Pain; 2017 Feb; 158(2):252-260. PubMed ID: 28092324
[TBL] [Abstract][Full Text] [Related]
12. Impaired chronic pain-like behaviour and altered opioidergic system in the TASTPM mouse model of Alzheimer's disease.
Aman Y; Pitcher T; Ballard C; Malcangio M
Eur J Pain; 2019 Jan; 23(1):91-106. PubMed ID: 29987897
[TBL] [Abstract][Full Text] [Related]
13. Inflammation and aging: can endocannabinoids help?
Marchalant Y; Brothers HM; Wenk GL
Biomed Pharmacother; 2008; 62(4):212-7. PubMed ID: 18400455
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016.
Dahlhamer J; Lucas J; Zelaya C; Nahin R; Mackey S; DeBar L; Kerns R; Von Korff M; Porter L; Helmick C
MMWR Morb Mortal Wkly Rep; 2018 Sep; 67(36):1001-1006. PubMed ID: 30212442
[TBL] [Abstract][Full Text] [Related]
15. Differences in analgesic use in community-dwelling persons with and without Alzheimer's disease.
Hamina A; Taipale H; Tanskanen A; Tolppanen AM; Tiihonen J; Hartikainen S
Eur J Pain; 2017 Apr; 21(4):658-667. PubMed ID: 27862681
[TBL] [Abstract][Full Text] [Related]
16. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.
Bisogno T; Di Marzo V
Curr Pharm Des; 2008; 14(23):2299-3305. PubMed ID: 18781980
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Cannabinoid System in Alzheimer's Disease.
Li S; Huang Y; Yu L; Ji X; Wu J
Curr Neuropharmacol; 2023; 21(3):715-726. PubMed ID: 35105293
[TBL] [Abstract][Full Text] [Related]
18. Pain interference and depressive symptoms in communicative people with Alzheimer's disease: a pilot study.
Wang J; Dietrich MS; Simmons SF; Cowan RL; Monroe TB
Aging Ment Health; 2018 Jun; 22(6):808-812. PubMed ID: 28466655
[TBL] [Abstract][Full Text] [Related]
19. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
Cooray R; Gupta V; Suphioglu C
Mol Neurobiol; 2020 Nov; 57(11):4878-4890. PubMed ID: 32813239
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
